[go: up one dir, main page]

ZA200906765B - Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer - Google Patents

Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer

Info

Publication number
ZA200906765B
ZA200906765B ZA200906765A ZA200906765A ZA200906765B ZA 200906765 B ZA200906765 B ZA 200906765B ZA 200906765 A ZA200906765 A ZA 200906765A ZA 200906765 A ZA200906765 A ZA 200906765A ZA 200906765 B ZA200906765 B ZA 200906765B
Authority
ZA
South Africa
Prior art keywords
cancer
alpha
treatment
combination therapies
quinoxaline
Prior art date
Application number
ZA200906765A
Other languages
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ZA200906765B publication Critical patent/ZA200906765B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200906765A 2007-04-11 2009-09-29 Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer ZA200906765B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
ZA200906765B true ZA200906765B (en) 2010-05-26

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906765A ZA200906765B (en) 2007-04-11 2009-09-29 Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer

Country Status (33)

Country Link
US (1) US8481001B2 (xx)
EP (1) EP2139483B9 (xx)
JP (2) JP5726515B2 (xx)
KR (1) KR101586774B1 (xx)
CN (2) CN103202842A (xx)
AU (1) AU2008239668B2 (xx)
BR (1) BRPI0810208A2 (xx)
CA (1) CA2684056A1 (xx)
CO (1) CO6140024A2 (xx)
CR (1) CR11099A (xx)
CY (1) CY1114608T1 (xx)
DK (1) DK2139483T3 (xx)
EA (1) EA019064B1 (xx)
EC (1) ECSP099723A (xx)
ES (1) ES2438998T3 (xx)
GT (1) GT200900263A (xx)
HR (1) HRP20131081T1 (xx)
IL (1) IL201211A (xx)
MA (1) MA31335B1 (xx)
ME (1) ME00937B (xx)
MX (1) MX2009010929A (xx)
MY (1) MY150797A (xx)
NI (1) NI200900184A (xx)
NZ (1) NZ580009A (xx)
PL (1) PL2139483T3 (xx)
PT (1) PT2139483E (xx)
RS (1) RS53020B (xx)
SI (1) SI2139483T1 (xx)
SV (1) SV2009003390A (xx)
TN (1) TN2009000399A1 (xx)
UA (1) UA98141C2 (xx)
WO (1) WO2008127594A2 (xx)
ZA (1) ZA200906765B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623768C (en) * 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
RS52939B (sr) * 2007-04-10 2014-02-28 Exelixis Inc. Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
PT2374802E (pt) * 2008-11-10 2014-07-10 Kyowa Hakko Kirin Co Ltd Inibidor de produção de quinurenina
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
AR084469A1 (es) 2010-07-09 2013-05-22 Exelixis Inc Combinaciones de inhibidores de quinasas para el tratamiento del cancer
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
KR20130141528A (ko) 2010-10-20 2013-12-26 메르크 세로노 에스에이 제네바 치환 ｎ-(3-아미노-퀴녹살린-2-일)-술폰아미드 및 이들의 중간체인 ｎ-(3-클로로-퀴녹살린-2-일)술폰아미드의 제조 방법
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
IN2014CN02671A (xx) * 2011-09-14 2015-07-03 Exelixis Inc
WO2013052699A2 (en) * 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
PH12014500897A1 (en) * 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
HK1201480A1 (en) * 2011-11-01 2015-09-04 Exelixis, Inc. N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide as phosphatidylinositol 3-kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
WO2013101964A1 (en) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
WO2013152717A1 (zh) 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
CN104557872B (zh) 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
WO2015123505A1 (en) 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
EP2351745A1 (en) * 2005-08-26 2011-08-03 Merck Serono S.A. Pyrazine derivatives and use as PI3K inhibitors
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
CA2623768C (en) * 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
BRPI0808013A2 (pt) 2007-02-22 2014-06-17 Merck Serono Sa Compostos de quinoxalina e uso dos mesmos
RS52939B (sr) * 2007-04-10 2014-02-28 Exelixis Inc. Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
IL201211A0 (en) 2010-05-31
HK1140141A1 (en) 2010-10-08
EP2139483B9 (en) 2014-05-21
NI200900184A (es) 2011-09-08
CR11099A (es) 2010-01-19
US8481001B2 (en) 2013-07-09
MA31335B1 (fr) 2010-04-01
AU2008239668A1 (en) 2008-10-23
JP2014074031A (ja) 2014-04-24
IL201211A (en) 2015-09-24
HRP20131081T1 (hr) 2013-12-20
CN103202842A (zh) 2013-07-17
BRPI0810208A2 (pt) 2014-10-21
CY1114608T1 (el) 2016-10-05
EP2139483A2 (en) 2010-01-06
JP5726515B2 (ja) 2015-06-03
PT2139483E (pt) 2013-12-27
CN101959516B (zh) 2013-05-08
CN101959516A (zh) 2011-01-26
NZ580009A (en) 2012-06-29
ES2438998T3 (es) 2014-01-21
UA98141C2 (ru) 2012-04-25
DK2139483T3 (da) 2014-01-13
US20110123434A1 (en) 2011-05-26
TN2009000399A1 (fr) 2010-12-31
KR20100019436A (ko) 2010-02-18
AU2008239668B2 (en) 2013-11-07
JP2010523669A (ja) 2010-07-15
WO2008127594A3 (en) 2009-04-30
KR101586774B1 (ko) 2016-01-19
GT200900263A (es) 2014-01-15
SV2009003390A (es) 2010-05-21
SI2139483T1 (sl) 2013-11-29
MX2009010929A (es) 2010-01-20
CA2684056A1 (en) 2008-10-23
PL2139483T3 (pl) 2014-02-28
EA200970935A1 (ru) 2010-04-30
ECSP099723A (es) 2010-03-31
CO6140024A2 (es) 2010-03-19
RS53020B (sr) 2014-04-30
EP2139483B1 (en) 2013-09-18
MY150797A (en) 2014-02-28
EA019064B1 (ru) 2013-12-30
WO2008127594A2 (en) 2008-10-23
ME00937B (me) 2012-06-20

Similar Documents

Publication Publication Date Title
IL201211A0 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
IL219253A (en) Benzodiazepine inhibiting bromodomain for cancer treatment
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
IL202317A0 (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
IL219992A0 (en) Combination therapy for treating cancer and dianostic assays for use therein
IL206563A0 (en) Medicament for the treatment of cancer of the pancreas
PL2040753T3 (pl) Inhibitory progastryny w leczeniu raka okrężnicy
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
PT3330383T (pt) Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
PL2320900T3 (pl) Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych
IL206189A (en) Compounds for use in cancer treatment
IL226363A0 (en) Compounds and methods for treating cancer
IL205339A0 (en) Compounds and methods for the treatment of cancer
GB0604794D0 (en) Spisulosine compounds for use in cancer therapy
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0604114D0 (en) Combinations for the treatment of cancer
GB0725166D0 (en) The use of ketoprofen in treating hemorrhoids